Abstract
The design and synthesis of a novel series of c-jun N-terminal kinase (JNK3) inhibitors is described. The development and optimization of the 2-phenoxypyridine series was carried out from an earlier pyrimidine series of JNK1 inhibitors. Through the optimization of the scaffold 2, several potent compounds with good in vivo profiles were discovered.
Copyright © 2011 Elsevier Ltd. All rights reserved.
MeSH terms
-
Drug Design*
-
Enzyme Activation / drug effects
-
Inhibitory Concentration 50
-
JNK Mitogen-Activated Protein Kinases / antagonists & inhibitors*
-
Models, Molecular
-
Molecular Structure
-
Protein Kinase Inhibitors / chemical synthesis*
-
Protein Kinase Inhibitors / chemistry
-
Protein Kinase Inhibitors / pharmacology*
-
Pyridines / chemical synthesis*
-
Pyridines / chemistry
-
Pyridines / pharmacology
-
Pyrimidines / chemical synthesis*
-
Pyrimidines / chemistry
-
Pyrimidines / pharmacology*
-
Structure-Activity Relationship
Substances
-
Protein Kinase Inhibitors
-
Pyridines
-
Pyrimidines
-
JNK Mitogen-Activated Protein Kinases